Observational Study in Patients With Functional Benign Prostatic Hyperplasia Symptoms Who Switched From Phytotherapy to ALNA® (Tamsulosin)

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Male

Summary

The objective of the observational study were to investigate the switch from phytotherapy to ALNA® after at least 4 weeks of phytotherapy and still presented with a symptom sum score of ≥ 8 points (International Prostate Symptom Score (IPSS))

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Tamsulosin

Criteria

Inclusion Criteria:

• Patients suffering from BPH symptoms

• Preceding treatment with a phytotherapeutic for at least 4 weeks

• IPSS sum score ≥ 8 points prior to treatment start with ALNA®

• Indication for a switch to treatment with ALNA® for a minimum period of 2 months

Exclusion Criteria:

• Patients fulfilling one of the general or specific contraindications listed in the ALNA® Summary of Product Characteristic, particularly patients with known hypersensitivities against tamsulosin hydrochloride or any other ingredient of the product, orthostatic dysregulation or severe liver insufficiency

• Patients receiving ALNA® within the 4 weeks prior to the start of the present observational study